Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026

Raymond Benza, MD, Chair of Cardiology, Sentara Health and Section Chief of Cardiology, Macon & Joan Brock Virginia Health Sciences, Eastern Virginia Medical School at Old Dominion University

“People living with debilitating pulmonary diseases often face substantial burdens as their disease progresses, compounded by complex treatment regimens and systemic side effects that can make the demands of everyday life increasingly difficult”

Raymond Benza, MD, Chair of Cardiology, Sentara Health and Section Chief of Cardiology, Macon & Joan Brock Virginia Health Sciences, Eastern Virginia Medical School at Old Dominion University

“As clinicians, we see firsthand the need to address the progressive nature of these diseases while considering the demands of long-term therapy. The PALM Clinical Development Program has the potential to demonstrate the impact of a novel, once-daily inhaled prostanoid therapy for patients across four serious pulmonary diseases.”

Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed

“As TPIP continues into the next stage of clinical development, this multi-indication PALM Clinical Development Program — the most ambitious clinical effort we are undertaking to date — is designed to break through treatment barriers that have historically limited innovation of prostanoid treatment for these complex pulmonary disorders”

Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed

“These four Phase 3 studies further evaluate TPIP's potential to meaningfully improve care and, if successful, emerge as the prostanoid of choice for clinicians and patients.”